Report: clinical trials will continue to play a key role in oncology device market
The U.S. interventional oncology device market will see strong growth, reaching a value of $760 million by 2023, according to Decision Resources Group. Rising cancer incidence rates, combined with the ineffectiveness of chemotherapy and demand for less invasive procedures, will support interventional oncology device uptake.
Other key findings include the importance of clinical trials—although many clinical studies have been performed to demonstrate the efficacy of interventional oncology devices, further studies are required for head-to-head device comparisons.
There also is demand for studies supporting effectiveness in new indications such as breast cancer, melanoma and neuroendocrine tumors. Large-scale trials also will be useful for driving adoption of combination treatments that use both ablation and embolization products.
Microwave ablation will experience the strongest growth of all interventional oncology device segments. This treatment offers the same benefits as radiofrequency ablation but boasts larger ablation zones, faster treatment times and more complete tumor destruction.
Radioembolization spheres and drug-eluting beads (DEBs) are seeing increasing interest, particularly with interventional radiologists for the treatment of liver cancer tumors. Growth may be fueled further if these products demonstrate levels of efficacy in clinical trials that support their use as first-line therapies.
Naushad Budhwani, Decision Resources Group analyst, said, "Partnerships, mergers and acquisitions in the interventional oncology device market are prominent as competitors attempt to penetrate untapped markets in the U.S. For example, AngioDynamics acquired Microsulis Medical to add microwave ablation to its ablation portfolio, BTG acquired Therasphere to add radioembolization particles to its embolization product line containing DEBs and microspheres and a distribution agreement was established between HS Medical and HealthTronics, which gives HealthTronics a growing thermal ablation product alongside its cryoablation products."